Related Experiment Videos
Cannabis use in sickle cell disease: a questionnaire study
Jo Howard1, Kofi A Anie, Anita Holdcroft
1Department of Haematology, Central Middlesex Hospital, London, UK. jo.howard@nwlh.nhs.uk
British Journal of Haematology
|September 22, 2005
Summary
Cannabis use for symptom relief is common in sickle cell disease (SCD) patients, primarily for pain and mood. While side effects like sedation occur, most patients are open to research on cannabinoids for SCD management.
Area of Science:
- Pharmacology and Therapeutics
- Hematology
- Pain Management
Background:
- Cannabinoids are emerging as potential treatments for various pain conditions.
- Sickle cell disease (SCD) involves significant pain and symptom burden.
- The role of cannabis in managing SCD symptoms requires further investigation.
Purpose of the Study:
- To assess the prevalence of cannabis use for symptom relief in SCD patients.
- To identify reasons for cannabis use and reported side effects.
- To gauge patient willingness to participate in cannabinoid research for SCD.
Main Methods:
- A structured, anonymous questionnaire was administered to SCD patients.
- Eighty-six adult patients with HbSS, HbSC, and HbSbetathalassaemia diseases participated.
- Data collected included cannabis usage patterns, motivations, and experienced side effects.
Main Results:
- 36% of SCD patients reported using cannabis in the past 12 months, primarily via smoking.
- Key reasons for use included pain reduction (52%) and relaxation/mood improvement (39%).
- Sedation and mood-related side effects were reported by 77% of users.
Conclusions:
- Cannabis is utilized by a significant portion of the SCD patient community for symptom management.
- Research into the therapeutic potential of cannabinoids for pain relief in SCD is warranted and would be acceptable to patients.
- Understanding patient perspectives is crucial for developing effective cannabinoid-based therapies for SCD.